Context: Thyroperoxidase antibody (TPOAb) positivity is the main risk factor for thyroid dysfunction during pregnancy and is consistently associated with premature delivery. However, the underlying mechanism is currently unknown. We hypothesized that TPOAb positivity may interfere with gestational thyroid stimulation induced by the pregnancy hormone human chorionic gonadotropin (hCG).
Results: In TPOAb-negative women, hCG was positively associated with FT4 and negatively with TSH in both cohorts (P , 0.0001). In contrast, in TPOAb-positive women, hCG was not associated with FT4 or TSH in either cohort (all P . 0.40; P for interaction TPOAb positive vs negative # 0.05). Overall, TPOAb positivity was associated with a 1.7-fold higher risk of premature delivery. TPOAb-positive women with an adequate response of FT4 to hCG (high FT4 concentration with high hCG concentration) did not have a higher risk of premature delivery. In contrast, TPOAb-positive women with an inadequate FT4 response to hCG (low FT4 concentration with high hCG concentration) had a 2.2-to 2.8-fold higher risk of premature delivery.
Conclusion: TPOAb-positive women display an impaired thyroidal response to hCG and this may explain the higher risk of premature delivery in these women. This abnormal response in TPOAbpositive women might suggest that these women require a different treatment approach than TPOAb-negative women. (J Clin Endocrinol Metab 102: 69-77, 2017) M aternal thyroid dysfunction occurs in 5% to 18% of all pregnancies and is associated with a higher risk of various adverse pregnancy outcomes, including premature delivery (1) (2) (3) (4) . During pregnancy, there is an increased demand for thyroid hormone (TH). This is met via stimulation of the thyroid by the pregnancy hormone human chorionic gonadotropin (hCG), which stimulates the thyroid via its affinity for the thyrotropin (TSH) receptor (5) . The rapid increase of hCG during early pregnancy results in an increase in serum free thyroxine (FT4) and a subsequent decrease in TSH concentrations as compared with a nonpregnancy state (5) .
Thyroperoxidase antibody (TPOAb) positivity, which reflects thyroid autoimmunity, is the most important risk factor for thyroid dysfunction. The current guidelines of the American Thyroid Association advocate levothyroxine treatment of subclinical hypothyroidism only in TPOAb-positive women, whereas the European Thyroid Association and Endocrine Society guidelines do not incorporate TPOAb status in their recommendations (1) (2) (3) .
Thyroid autoimmunity decreases the functional capacity of the thyroid gland, ultimately leading to thyroid failure and hypothyroidism. Before the onset of hypothyroidism, the decreased capacity may become apparent during a state of increased demand, such as early pregnancy. This increased demand is mediated, in part, by factors that lower TH availability, such as an increase in thyroxine-binding globulin, thyroxine transport to the fetus, and TH degradation by placental deiodinase type 3. On the other hand, high concentrations of hCG stimulate the thyroid, overall leading to a net increase in TH availability during early pregnancy. The decreased thyroid functional capacity due to autoimmunity is supported by observations that TPOAb-positive women have higher median TSH concentrations and are at approximately 8-fold higher risk of developing subclinical hypothyroidism during pregnancy (6, 7). Poppe et al. (8) (N = 35) showed that TPOAb-positive women undergoing assisted reproductive therapy have an attenuated FT4 response to synthetic hCG administration and Glinoer et al. (6) demonstrated an attenuation in the classical TSH dip during early pregnancy in TPOAb-positive women. However, the effects of TPOAb positivity on thyroid stimulation by hCG during pregnancy are currently unknown.
It consistently has been shown in different studies, including the Generation R study, that TPOAb positivity is associated with a higher risk of premature delivery (2-4, 9-11). However, the pathophysiological mechanism underlying this association remains to be elucidated. Because TPOAbs increase the risk of thyroid dysfunction, the higher risk of premature delivery in TPOAb-positive women may be mediated via alterations in thyroid function. Nevertheless, we previously showed that the association of TPOAb positivity with premature delivery does not change after additional adjustment for TSH and FT4, which might suggest an effect independent of maternal thyroid function (10) . An alternative explanation would be that TPOAb positivity reflects a higher susceptibility to autoimmunity in general and that autoimmune processes confound the association of TPOAb positivity with premature delivery (12) (13) (14) .
We hypothesized that TPOAb-positive women have an inappropriate thyroidal response to hCG stimulation (as a marker for an abnormal thyroid functional capacity) and that this would be reflected by an attenuated association of hCG with FT4 and TSH during pregnancy in TPOAb-positive women. Moreover, we speculated that an attenuated association of hCG with FT4 and TSH may underlie the association of TPOAb positivity with premature delivery.
Materials and Methods

Design
We tested these hypotheses in 2 large prospective cohorts: the Generation R Study, a population-based prospective cohort from early fetal life onwards in Rotterdam, The Netherlands (15) ; and in the Holistic Approach to Pregnancy and the First Postpartum Year (HAPPY) study, a population-based prospective pregnancy cohort in the Eindhoven area of The Netherlands (16) .
In the Generation R study, 7069 women with a delivery date between April 2002 and January 2006 were enrolled during early pregnancy (,18 weeks) in hospitals and midwife practices (15) . Blood samples were drawn in 6398 of these women and enough material was present in the samples of 6278 women to measure TSH, FT4, TPOAb, or hCG concentrations. Women with twin pregnancies (n = 128), women who underwent fertility treatment (n = 76), women with preexisting thyroid disease or thyroid (interfering) medication use (n = 89; assessed 3 times during pregnancy by questionnaire), women with missing data on gestational age at birth or a difference of more than 1 week in gestational age at blood sampling between the hCG and TSH or FT4 samples (n = 47) were excluded. For analyses on the association of hCG with thyroid function, we performed a complete-case analysis in 5435 women during early pregnancy (median, week 12; 95% range, 11 to 18) in which enough serum was available to measure TSH, FT4, TPOAbs, and hCG concentrations. Gestational age at birth was obtained for .99% of all participating mother-child pairs. The Netherlands is generally an iodine-sufficient country, as reflected by the iodine status in the Generation R study (median population urinary iodine concentration, 225 mg/L) (17) .
In the HAPPY study, eligible mothers were those who presented at any of 17 primary care community midwife practices in the South-East Brabant area from January 2013 until September 2014 (16) . A total of 2130 women were enrolled (,25 weeks of pregnancy; 95% enrolled ,18 weeks of pregnancy) and blood samples from early pregnancy were available for 1706 women. In 1563 women, a blood sample from late pregnancy (median week, 32; 95% range, 31 to 35) was also available. TSH, FT4, and hCG concentrations were measured during early pregnancy in 1706 women with a singleton pregnancy (median week, 13; 95% range, 11 to 18) and during late pregnancy in 1606 women with a singleton pregnancy (median week, 33; 95% range, 31 to 35). Women with pre-existing thyroid disease or thyroid (interfering) medication use (n = 43) were excluded; no data were available on fertility treatment. Further details on data ascertainment are presented in the Supplemental Appendix.
Clinical outcomes
To study whether differences in the association of hCG with thyroid function may explain the association of TPOAb positivity with a higher risk of premature delivery, we used the same study population we have previously used to study the associations of TPOAb positivity with premature delivery (10) . In short, data on gestational age at birth were obtained from community midwives, obstetricians, and hospital registries. Premature delivery was defined as the onset of premature labor before the 37th week of gestation. We also performed a sensitivity analysis on spontaneous premature delivery, which was defined as a spontaneous onset of premature labor before the 37th week of gestation and included women who delivered without induction of labor or an elective cesarean section. After exclusion of women with twin pregnancies (n = 128), pre-existing thyroid disease, or thyroid-interfering medication usage (n = 89); women undergoing fertility treatment (n = 76) (10); and women with hCG measurement not performed within the same week as thyroid function measurement (n = 15), data on gestational age at birth and TSH, FT4, TPOAb, or hCG concentrations measured in the same sample were available for 5956 women from the Generation R study (missing data on serum TSH, FT4, or hCG concentration [randomly missing due to lack of serum in 6.3%, 5.7%, and 3.5%, respectively] were imputed to allow comparison of the new analyses to previously published analyses) (10) . Sensitivity analyses for the risk of premature delivery were performed in nulliparous women only because they are at higher risk for TPOAb positivity (18)), and in women with spontaneous delivery. We were not able to study the association of TPOAb positivity with premature delivery in the HAPPY study because only 125 women were TPOAb positive (7.3%) and 70 women (4.2%) had a premature delivery. Between-study differences in thyroid function, and TPOAb and hCG measurements (i.e., serum vs plasma, assay differences) did not allow for meta-analysis.
Statistical analysis
The association of hCG concentrations with FT4 and TSH concentrations were studied using linear regression models. We tested for potential effect modification in the association of hCG with FT4 or TSH by TPOAb positivity by adding to the model the product interaction term for TPOAb positivity (yes/no) multiplied by hCG. Gestational age at birth was studied using multivariable linear regression models. Premature delivery was studied using multivariable logistic regression models. We investigated interaction between TPOAb positivity and hCG concentration for gestational age at birth or premature delivery by introducing a product term to the model and subsequent plotting of interactions. To investigate if differences in the risk of premature delivery between TPOAb-positive and TPOAb-negative women differed according to FT4 and hCG concentration, all 2-way and the 3-way interactions of FT4, hCG, and TPOAb positivity (yes/no) were added to the models. In case of a statistically significant 3-way interaction, analyses of TPOAb positivity as a risk factor for premature delivery were stratified according to FT4 concentrations standardized to hCG concentration.
We defined the expected thyroidal response to hCG stimulation cross-sectionally based on the assumption that the predicted means in the whole population are the best approximation of hCG-mediated FT4 changes in an individual. FT4 concentrations standardized to hCG concentration were defined by the residuals of a regression model in which hCG was regressed on FT4 in TPOAb-negative women. Because the response of FT4 to hCG is most pronounced in women with high concentrations of hCG, women with relatively low hCG concentrations in this cross-sectional study were more prone to misclassification for their expected thyroidal response to hCG. In other words, the FT4 response in women with low hCG may change when higher hCG concentrations are present. Therefore, we also performed the stratified analyses on the risk of premature delivery in women with an hCG concentration above the median only (median hCG concentration in Generation R study, 45,000 IU/L). Between-group median TPOAb concentrations were calculated using the Mood median test using log-transformed TPOAb concentrations. Further details about the statistical analyses are reported in the Supplemental Appendix.
All statistical analyses were performed using Statistical Package of Social Sciences version 21.0 for Windows (SPSS, Chicago, IL) or using R statistical software version 3.03 (packages rms, hmisc and visreg; https://www.r-project.org/). press.endocrine.org/journal/jcem
Results
In the Generation R study, after exclusions, 5956 women were enrolled during early pregnancy (median, 13.2 weeks; 95% range, 9.6 to 17.6 weeks; Fig. 1 ). There was no difference in urinary iodine to creatinine ratio between TPOAbnegative and positive-women (283 vs 291 mg/g; P = 0.61). In the HAPPY study, after exclusions, 1663 women from were enrolled during early pregnancy (median, 13.0 weeks; 95% range, 11.0 to 19.0) and 1563 women during late pregnancy (median, 32.3 weeks; 95% range, 31.3 to 34.9; Fig. 1 ).
Further details on subject characteristics are shown in Supplemental Table 1 .
Association of hCG with thyroid function according to TPOAb status In both populations, there was a positive association of hCG with FT4 in TPOAb-negative women but not in TPOAb-positive women, during early pregnancy (P for interaction , 0.001 in the Generation R study and 0.036 in the HAPPY study; Fig. 2 ). Through negative feedback, the hCG-mediated increase in serum FT4 is subsequently responsible for the decrease in serum TSH (5) . There was a negative association of hCG with TSH in TPOAb-negative women but not in TPOAb-positive women during early pregnancy in both populations (P for interaction = 0.0077 in the Generation R study and 0.0016 in the HAPPY study; Fig. 3) .
hCG concentrations were substantially lower in late pregnancy than in early pregnancy (median during late pregnancy, 14,000 IU/L vs 58,000 IU/L during early pregnancy). During late pregnancy, hCG was not associated with FT4 and the negative association of hCG with TSH was attenuated as compared with early pregnancy [Supplemental Fig. 1(A) and 1(B) ]. Longitudinal analyses, comparing the change in hCG between early and late pregnancy in the HAPPY study, showed that the decrease in hCG was associated with a decrease in FT4 and with an increase in TSH [Supplemental Fig. 1(C) and 1(D) ].
TPOAb positivity and the risk of premature delivery
We subsequently aimed to investigate the potential clinical implications of differences in the thyroidal response to hCG stimulation for the risk of an adverse outcome. Therefore, we investigated if an impaired thyroidal response to hCG may underlie the higher risk of premature delivery in TPOAb-positive women by investigating effect modification between hCG and FT4 in logistic regression models for premature delivery.
In TPOAb-positive women, differences in hCG modified the association of FT4 with premature delivery (P for interaction = 0.050), whereas this was not the case in TPOAb-negative women (P for interaction = 0.33). This effect modification differed between TPOAbpositive and TPOAb-negative women (P for 3-way interaction = 0.012 [Supplemental Table 2 ]; similar results were obtained with gestational age at birth continuously, P for 3-way interaction = 0.045 [data not shown]). Figure 4 depicts hCG and FT4 for all women included from Generation R, split into TPOAb-negative women (gray dots with gray dotted regression line) and TPOAbpositive women (colored dots). TPOAb-positive women were grouped according to their expected thyroidal response to hCG as compared with the mean of the TPOAbnegative population (expected thyroidal response was defined by the expected mean FT4 based on hCG, ranging from green, relatively high FT4 for hCG reflecting an above average expected thyroidal response to hCG, to red, relatively low FT4 for hCG reflecting a below average expected thyroidal response to hCG.
The overall risk of premature delivery in TPOAbpositive women was 1.7-fold higher than in TPOAbnegative women (odds ratio, 1.66; 95% confidence interval, 1.03 to 2.54; P = 0.027). However, when stratified according to the observed expected thyroidal response, TPOAb-positive women with an adequate expected thyroidal response to hCG (Fig. 4 , green group) did not have a higher risk of premature delivery (Table 1) . On the other hand, TPOAb-positive women with an inadequate expected thyroidal response to hCG (Fig. 4 , orange and red group) had a 2.2-and 2.3-fold higher risk of premature delivery, respectively (Table 1) press.endocrine.org/journal/jcemnonincreased risk of premature delivery in TPOAb-positive women with an adequate expected thyroidal response to hCG and a 2.3-to 2.8-fold increased risk of premature delivery in TPOAb-positive women with an inadequate expected thyroidal response to hCG (Table 1) . Furthermore, sensitivity analyses showed that the differences in the risk of premature delivery were larger in nulliparous women (a risk factor for TPOAb positivity) and similar for the risk of spontaneous premature delivery (Table 2) .
Discussion
In this study, we investigated the association of hCG with thyroid function in TPOAb-positive and TPOAb-negative women during early and late pregnancy, using data from 2 prospective population-based cohorts. The main finding was that in TPOAb-positive women, hCG is not associated with FT4 or TSH, which is in contrast to well-known, strong associations of hCG with FT4 and TSH in TPOAbnegative women. This difference suggests that TPOAb positivity is associated with an impaired thyroidal response to hCG during pregnancy. Subsequently, we show that TPOAb-positive women with an impaired expected thyroidal response to hCG (lower FT4 than expected for hCG) had a higher risk of premature delivery. In contrast, TPOAb-positive women with an adequate expected thyroidal response to hCG did not have a higher risk of premature delivery. Thyroid autoimmunity decreases the functional capacity of the thyroid gland. Outside of pregnancy, early stages of thyroid autoimmunity/TPOAb positivity are marked by a gradual increase in TSH concentrations, which is necessary to keep TH availability stable. However, in euthyroid individuals, a decreased thyroid functional capacity may be exposed during a state of increased thyroidal demand such as pregnancy, when high hCG concentrations lead to an increase in thyroid stimulation and TH production. As opposed to the increase in TSH concentrations seen in TPOAb-positive women outside of Colors refer to data presentation in Figure 4 . a Defined in comparison with mean regression line, decreased: , 21 SD; low normal: 21 to 0 SD; high-normal: 0 to 1 SD; increased: . 1 SD.
pregnancy, TSH-receptor stimulation due to hCG during pregnancy has a rapid onset that leads to an increase in TH availability and occurs simultaneously with physiological factors that concomitantly decrease TH availability. We show that high hCG concentrations during early pregnancy in TPOAb-positive women were not associated with higher FT4 or lower TSH concentrations, which is in contrast to the clear hCG response in TPOAbnegative women. These data are in line with a previous study by Poppe et al. (8) that showed, in 35 women who received exogenous hCG for assisted reproductive therapy, TPOAb-positive women had an attenuated FT4 response compared with TPOAb-negative women. Peak hCG concentrations are found between approximately weeks 9 and 12 of pregnancy. Within this critical period of pregnancy, placentation takes place and the fetus depends on maternal THs for its brain development. Because of this timing, an impaired response to hCG stimulation may lead to a relative shortage of THs, particularly during the peak of hCG concentrations. A relative TH shortage during this critical phase in pregnancy may have detrimental effects mimicking those of an absolute TH shortage (1) (2) (3) (4) .
Premature delivery has been identified as the largest direct cause of child morbidity and mortality in almost all high-and middle-income countries (19) . Furthermore, it is an important risk factor for psychiatric, metabolic, cardiovascular, and renal diseases later in life (20) (21) (22) .
The results in this paper provide evidence that the association of TPOAb positivity with a higher risk of premature delivery is mediated by alterations in thyroid function. We demonstrate that there is considerable variation of FT4 response to hCG stimulation within the group of TPOAb-positive women. Subsequent analyses suggest that only TPOAb-positive women with an inadequate thyroidal response to hCG (FT4 lower than expected according to hCG) have a higher risk for premature delivery. Interestingly, the benefit of treating TPOAb-positive women with levothyroxine for pregnancy outcome is being studied in 2 clinical trials (Randomized Controlled Trial of the Efficacy and Mechanism of Levothyroxine Treatment on Pregnancy and Neonatal Outcomes in Women with Thyroid Antibodies [TABLET], ISRCTN: 15948785; and the T4LIFE trial, Netherlands Trial Register no. NTR3364). Our findings suggest that particularly those TPOAb-positive women who have a decreased expected thyroidal response to hCG may benefit from levothyroxine treatment in these trials.
To our knowledge, this is the first study that has investigated the mechanism behind the association of TPOAb positivity and a higher risk of premature delivery. The main strength of this study is the large number of unselected subjects from 2 independent cohorts with detailed data available on their phenotype, thyroid function, thyroid function determinants, and adverse clinical outcome. This enabled us to adjust analyses for various confounding Colors refer to data presentation in Figure 1 . a Defined in comparison with mean regression line, decreased: , -1 SD; low normal: 21 to 0 SD; high-normal: 0 to 1 SD; increased: . 1 SD.
b Not enough events for reliable analysis.
doi: 10.1210/jc.2016-2942 press.endocrine.org/journal/jcemfactors and to investigate higher-order interactions of continuous variables. A potential limitation of this study is that only a single measurement of maternal thyroid function and hCG was available in the Generation R study. In theory, FT4 concentrations during early pregnancy may have been transient, not reflecting TH availability during the full course of pregnancy. However, a single measurement mimics clinical practice, during which decisions need to be made as early in pregnancy as possible. Moreover, hCG was only associated with FT4 during early pregnancy and not during the third trimester, when hCG concentrations are much lower. This suggests that differences in expected thyroidal response between TPOAb-positive and TPOAb-negative women are particularly relevant during early pregnancy when hCG reaches peak concentrations.
Another limitation of the cross-sectional design may have been that not all women had hCG concentrations at the time of blood measurement that were high enough to truly distinguish differences in FT4 response between TPOAb-positive and TPOAb-negative women. To reduce misclassification, we performed all analyses in women with hCG concentrations above the population median, which showed that effect estimates were amplified.
Monitoring the increase in FT4 concentrations during pregnancy may be a sensitive way to identify women with a relative thyroid dysfunction (i.e., low FT4 relative to hCG), particularly for TPOAb-positive women. Such monitoring may be improved through further studies into determinants of the differences in thyroidal response to hCG within the group of TPOAbpositive women-for example, the co-occurrence of thyroid-stimulating antibodies (23) . However, given that hCG peaks early in pregnancy and most women first attend a pregnancy clinic during or after this period, timely initiation of treatment will most likely not be feasible. The development of a test using thyroid stimulation before pregnancy may help identify TPOAb-positive women who are particularly at risk of developing thyroid dysfunction during pregnancy. Such a test would also allow for timely treatment that could even be started before pregnancy.
In conclusion, hCG is not associated with FT4 or TSH in TPOAb-positive women, suggesting that TPOAb positivity considerably impairs gestational thyroid stimulation by hCG. In particular, those TPOAb-positive women who had a low FT4 relative to their hCG had a higher risk of premature delivery. These results are the first evidence that TPOAb positivity results in adverse pregnancy outcomes via alterations in gestational thyroid function. The abnormal thyroidal response in TPOAb-positive women might suggest that these women require a different treatment approach than TPOAb-negative women. Future studies are needed to replicate these findings and investigate the potential benefit for screening and subsequent treatment strategies.
